Ondansetron otc substitute full#
Ondansetron otc substitute professional#

Studies suggest that scopolamine patches work just as well as dimenhydrinate, but better than meclizine.

Ondansetron otc substitute full#

View the full FDA Drug Safety Communication on FDA. Medication treatment options include prescription scopolamine patches (Transderm Scop) and over-the-counter (OTC) antihistamine pills, like dimenhydrinate (Dramamine).

Ondansetron otc substitute professional#

Advise patients to contact a healthcare professional immediately if they experience signs and symptoms of an abnormal heart rate or rhythm while taking Zofran (ondansetron). ECG monitoring is recommended in patients with electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia), congestive heart failure, bradyarrhythmias, or patients taking concomitant medications that prolong the QT interval. The use of Zofran (ondansetron) should be avoided in patients with congenital long QT syndrome. These medications help to suppress the vomiting reflex. In addition, Torsade de Pointes, an abnormal heart rhythm, has been reported in some patients receiving ondansetron. Ondansetron (Zofran) Granisetron (Sustol, Sancuso) Dolasetron (Anzemet) Palonosetron (Aloxi) Neurokinin (NK-1) receptor antagonists. ECG changes including QT interval prolongation have been seen in patients receiving Zofran (ondansetron). Additionally, recommendations for ECG monitoring in patients with electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia), congestive heart failure, bradyarrhythmias, or in patients taking other medications that can lead to QT prolongation, are being included in the labels. The labels are being revised to include a warning to avoid use in patients with congenital long QT syndrome, because these patients are at particular risk for Torsade. The Zofran (ondansetron) drug labels already contain information about the potential for QT prolongation. Additional label changes may result after the additional information has been reviewed. Although, not every person faces the side effects of ONDANSETRON, and even some of the unpleasant effects of ONDANSETRON do not require medical attention. The results from this study are expected to be available in the summer of 2012. A person taking ONDANSETRON often experience side effects that include a feeling of warmth, constipation, headache, diarrhoea, headache, drowsiness, feeling of tiredness. The manufacturer of Zofran (GlaxoSmithKline) is being required to conduct a thorough QT study to assess the potential for the drug to prolong the QT interval. Ondansetron may increase the risk of developing abnormal changes in the electrical activity of the heart, which can result in a potentially fatal abnormal heart rhythm.įDA has reviewed all available information and is making interim changes to the drug labels. FDA is informing the public of an ongoing safety review of the anti-nausea drug Zofran (ondansetron, ondansetron hydrochloride and their generics).